title: Comparative immunohistochemical analysis of aurora-A and aurora-B expression in human glioblastomas. Associations with proliferative activity and clinicopathological features.
abstract: In the present study, we carried out a comparative immunohistochemical analysis of aurora-A and aurora-B expression in 40 patients with primary glioblastomas, and attempted to identify any associations with Ki-67 index and the patients' clinical features. The impact of various treatment modalities and proliferative activity on patient outcome was also assessed. Immunohistochemistry was carried out using formalin-fixed and paraffin-embedded tissue sections. Aurora-A expression was higher in tumors with high Ki-67 expression (p=0.01) and was positively, though marginally, related to aurora-B expression (p=0.085). Aurora-B expression was not linked to Ki-67 expression (p=0.182). Lower aurora-A immunohistochemical expression, chemotherapy administration, and tumor localization in one lobe of the brain implied a greater probability of patient survival in univariate analysis (p=0.044, p=0.008, p=0.041, respectively). Ki-67 and aurora-B immunoreactivities were not associated with patient survival (p=0.918 and p=0.539, respectively). To our knowledge, for the first time, the association between aurora-A and aurora-B expression, the correlation of aurora-A with Ki-67 index, and the prognostic impact of aurora-A expression were assessed in glioblastomas. Although we addressed a prognostic connotation of aurora-A, we presume that aurora-A and aurora-B play a complicated role within glioblastomas. Further examinations of larger series are required, so that definite conclusions can be drawn.
authors.affiliation: Department of Histology and Embryology, National and Kapodistrian University of Athens, Medical School, Athens, Greece. vassilissamaras@yahoo.gr
authors.forename: Vassilis
authors.initials: V
authors.lastname: Samaras
authors.forename: Angeliki
authors.initials: A
authors.lastname: Stamatelli
authors.forename: Efstathios
authors.initials: E
authors.lastname: Samaras
authors.forename: Christos
authors.initials: C
authors.lastname: Arnaoutoglou
authors.forename: Marianthi
authors.initials: M
authors.lastname: Arnaoutoglou
authors.forename: Ioanna
authors.initials: I
authors.lastname: Stergiou
authors.forename: Paraskevi
authors.initials: P
authors.lastname: Konstantopoulou
authors.forename: Vassilis
authors.initials: V
authors.lastname: Varsos
authors.forename: Andreas
authors.initials: A
authors.lastname: Karameris
authors.forename: Calypso
authors.initials: C
authors.lastname: Barbatis
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D001932:Brain Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000628:therapy; D049109:Cell Proliferation; D002540:Cerebral Cortex / Q000378:metabolism*; D003131:Combined Modality Therapy; D005260:Female; D005909:Glioblastoma / Q000378:metabolism* / Q000401:mortality / Q000628:therapy; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D019394:Ki-67 Antigen / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism*; D018709:Statistics, Nonparametric; D016896:Treatment Outcome
chemical_list: D019394:Ki-67 Antigen; D017346:Protein Serine-Threonine Kinases